ABSTRACT -PURPOSE. The effect of CCl 4 -induced experimental hepatic injury (CCl 4 -EHI) on the pharmacokinetics of daunorubicin was investigated systemically in rats, in an attempt to elucidate the major determinants of the effect of CCl 4 -EHI on the pharmacokinetics of the drug. METHODS. CCl 4 -EHI was induced in rats by a single intraperitoneal injection of CCl 4 (1mL/kg rat), and a 24 h fasting period. Daunorubicin was administered intravenously to control and EHI rats at a dose of 11.3 mg/mL/kg and the in vivo pharmacokinetics was studied. The in vitro uptake of the drug into isolated hepatocytes and canalicular liver plasma membrane (cLPM) vesicles, as well as the liver microsomal degradation of the drug, were also determined. RESULTS. The area under the plasma concentration-time curve (AUC) of daunorubicin was increased by 1.6 times, resulting in a 34% decrease in the systemic clearance (CL) in rats with CCl 4 -EHI. The apparent biliary (CL bile ) and urinary (CL urine ) clearance of the drug were unchanged, whereas the AUC of daunorubicinol, the major metabolite of daunorubicin, was decreased by 66% in rats with CCl 4 -EHI. EHI seemed to affect the hepatobiliary elimination of the drug in several ways: the in vitro intrinsic sinusoidal uptake clearance was decreased by 20%; the in vitro intrinsic canalicular excretion clearance of the drug was increased by 1.7 times; and the in vitro liver microsomal degradation of daunorubicin was significantly retarded. CONCLUSIONS. CCl 4 -EHI appears to impair the hepatic metabolism of daunorubicin, thereby decreasing the CL and increasing the AUC of daunorubicin.
INTRODUCTION
Daunorubicin is one of the most important and widely used anticancer drugs and is used to treat breast and lung carcinoma, lymphoma, and leukemia (1) . However, the clinical use of daunorubicin is often limited by serious problems such as chronic cardiomyopathy and congestive heart failure (2) . The drug is predominantly metabolized by aldo-keto reductase, glycosidases, and CYP 2B1 in the liver, and the metabolites, as well as daunorubicin, undergo extensive biliary excretion (3, 4) . In fact, more than 80% of the intravenous dose of the drug is recovered in the bile as parent and metabolite forms, whereas the recovery in urine is limited (i.e., 10% of the dose) (5, 6) . Liver diseases likely affect the pharmacokinetics of drugs that are mainly metabolized or excreted in the liver (7, 8) . To study the pharmacokinetics of drugs in hepatic disease, an experimental hepatic injury (EHI) induced by a single dose of carbon tetrachloride (CCl 4 ) is a widely used model of hepatic disease (9, 10) . CCl 4 leads to the acute, reversible necrosis of centrilobular hepatocytes, followed by liver regeneration (11) . In response to hepatotoxicity, inflammation occurs via the activation of Kupffer cells and the release of inflammatory mediators such as cytokines, which are thought to alter the expression and activity of several liver-derived proteins (12, 13) . Recently, multiple alterations in the expression of organic anion transporters by EHI have been reported. For example, the expression of Na + /taurocholate cotransporting polypeptide (ntcp), organic anion transporting polypeptide 1 (Oatp1), and Oatp2 decreases, whereas .that .Oatp4 .and .bile .salt .export .pump ________________________________________ (Bsep) remains unchanged (14, 15) . The expression of multidrug-resistance related protein (Mrp2) is not affected for hepatic microsomes (14) , whereas a significant decrease is observed for the canalicular membrane (15) . In addition, our previous studies has revealed that the in vitro transport of organic cations across the sinusoidal membrane is decreased as a result of CCl 4 -EHI (16) , while the transport activity of Pglycoprotein (P-gp) in the canalicular membrane is increased by CCl 4 -EHI (15) .
In addition, CCl 4 -EHI markedly alters the liver enzyme system, changing the pharmacokinetic properties of hepatically eliminated drugs such as propranolol (17) . It has been also reported that the expression of cytochrome P450 (CYP) in the rat is significantly reduced in CCl 4 -EHI (18). Jiko et al. (10) have reported that testosterone 6β-hydroxylase activity via CYP3A is reduced by 92% in rat liver microsomes with CCl 4 -EHI, and liver dysfunction caused by hepatic failure affected the pharmacokinetics of paclitaxel in vivo. Therefore, to investigate the effects of hepatic injury on the pharmacokinetics of daunorubicin systemically, we examined the effect of CCl 4 -EHI on the unit processes of hepatic disposition of the drug (e.g., systemic pharmacokinetics, sinusoidal uptake, canalicular excretion, and hepatic metabolism) in vivo and in vitro. .
METHODS AND MATERIALS

Materials
Induction of experimental hepatic injury by CCl 4
Rats were injected intraperitoneally with a single dose of CCl 4 (1 mL/kg) as a 50% (v/v) solution in olive oil and then fasted for 24 h, but with free access to water. The control animals received a corresponding dose of olive oil, followed by the same experimental protocol. The induction of experimental hepatic injury was confirmed by a 4.6-times increase in the activity of alanine aminotransferase (ALT; from 53.7±8.8 to 247.1±92 unit/mL serum, n=6) and a 6-times increase in the activity of aspartate aminotransferase (AST; from 107.9±6.9 to 665.1±74 unit/mL serum, n=6). The activities of ALT and AST were measured using modified method of Reitman and Frankerl (19) with a commercial colorimetric determination kit (Yeoung Dong Pharm. Co., Seoul, Korea).
Pharmacokinetic study
Under ketamine anesthesia (50 mg/kg, i.p. injection), the femoral arteries and veins of rats (n=5) were cannulated with PE-50 polyethylene tubing (Intramedic, Sparks, MD), and a 3% (w/v) mannitol saline solution was infused through the femoral vein cannula at a rate of 10 mL/h/kg to obtain a constant urine flow. After opening the abdomen, the bile duct and ureters were cannulated with PE-10 polyethylene tubing (Intramedic, Sparks, MD). After recovery from the surgery, the animals were given daunorubicin hydrochloride (11.3 mg/mL/kg, dissolved in distilled water) via the femoral vein. Blood samples (200 µL) were collected from the femoral artery at 0, 1, 5, 10, 20, 30, 45, 60, 120, and 180 min, and bile and urine were collected for 30-min periods up to 3 h. The total volume of blood withdrawn was 2 mL. After each blood sampling, 150 µL of heparinized saline (20 units/mL) was injected via the catheter to flush the catheter and prevent blood clotting, and the fluid loss was compensated for with an injection of saline at each collection via the femoral vein. Body temperature was maintained using a heat lamp. Blood samples were centrifuged immediately, and 100 µL aliquot of each plasma sample was collected and stored at -70 °C until analysis.
Uptake of daunorubicin into isolated hepatocytes
Isolated hepatocytes were obtained from control (n=3) and CCl 4 -EHI (n=3) rats according to a previously described procedure (20) . The cell suspension (2 mL, 2.5-3.0×10 6 cells/mL) was preincubated in the medium for 5 min at 37 °C and a 20-µL aliquot of a [
3 H]daunorubicin solution with various initial radioactivities was added to the suspension to give a final medium concentration of 1-100 µM as daunorubicin hydrochloride (0.004-0.4 µCi). While incubating each suspension at 37 °C, 200-µL aliquots of the suspension were sampled at 30, 60, 90, and 120 seconds, and the level of radioactivity in the hepatocytes was determined as described previously (20) . The amount of daunorubicin in hepatocytes (expressed as pmole/10 6 cells) was then plotted against time for each suspension. The initial uptake rate of the drug into hepatocytes, calculated from the linear portion of the plot, was then plotted against the initial concentration of the drug in the medium.
Uptake of daunorubicin into cLPM vesicles
Canalicular liver plasma membrane (cLPM) vesicles were prepared from control (n=3) and CCl 4 -EHI rats (n=3) according to the method of Inoue et al. (21) and characterized as described previously (15) . Uptake was initiated by adding 40 µL of membrane suspension buffer (MSB, 250 mM sucrose, 10 mM Hepes, 10 mM Tris, 10 mM MgCl 2 , and 0.2 mM CaCl 2 , pH 7.4) containing 0.2 µM daunorubicin hydrochloride (0.035 µCi) with an ATP-regenerating system (1.2 mM ATP, 3 mM phosphocreatine, and 3.6 µg/100 µL creatine phosphokinase) to the preincubated vesicle suspension. At predetermined times, the uptake was quenched by adding 1 mL of ice-cold suspension containing 20 µM daunorubicin. The entire sample was then rapidly filtered through an MF-MEMB filter (0.45-µm pore size, 25-mm diameter, Seoul Science, Seoul, Korea) that had been presoaked in ice-cold MSB for 2 h. After washing with 10 mL of ice cold MSB, the filter was dissolved in 4 mL of scintillation cocktail (Ultima Gold, Perkin-Elmer), and the radioactivity of the mixture was determined by liquid scintillation counting (Wallac 1409, PerkinElmer). The initial uptake rate of the drug was obtained from the linear portion (generally up to 1 min) of the temporal profile, and then plotted against the initial concentration of the drug in the medium. The concentration dependency of the ATP-dependent initial uptake rate of daunorubicin was examined for the concentration range of 5-500 µM.
Liver microsomal degradation of daunorubicin
Rat liver microsomes were prepared using conventional methods (22) . The liver was perfused with ice-cold isolation buffer (0.154 M KCl, 50 mM Tris-HCl, pH 7.4), homogenized in four volumes of isolation buffer, and then centrifuged at 10,000 g for 20 min at 4 °C. The supernatant was centrifuged at 100,000 g for 60 min at 4 °C, and the microsomal pellet was washed by resuspension in fresh buffer and centrifuged again at 100,000 g for 60 min at 4 °C. Liver microsomes were resuspended in two volumes of 0.12 M Tris (pH 7.4), and 1-mL aliquots were stored frozen at -70 °C. The microsomal protein and total CYP content of the liver microsomes were measured using the methods of Lowry et al. (23) and Omura and Sato (24) , respectively. Microsomes (0.5 mg of total protein) were diluted to a final volume of 460 µL using 50 mM Tris-HCl buffer (pH 7.4), and 30 µL of TrisHCl buffer containing an NADPH-regenerating system (1 mM NADP + , 3 mM glucose-6-phosphate, 3 mM MgCl 2 , and 2 U/mL glucose-6-phosphate dehydrogenase) was added, followed by a further incubation for 15 min at 37 °C in a shaking water bath (25) . After preincubating of the microsomal suspension for 5 min at 37 °C, the microsomal incubation was started by adding 10 µL of 1.5 mM daunorubicin hydrochloride. The reaction was terminated at predetermined times (i.e., 0, 5, 10, and 15 min) by placing the incubation tubes on ice and immediately adding 1 mL of ice-cold acetonitrile and centrifuging at 10,000 rpm for 10 min. A 50-µL aliquot was injected into the HPLC system to determine the residual daunorubicin.
HPLC assay of daunorubicin and daunorubicinol
The concentrations of daunorubicin in plasma, bile and urine, as well as those of daunorubicinol in plasma, were quantified by HPLC with a fluorescence detector, as previously described (15) . Briefly, a 100-µL aliquot of the biological samples (i.e., plasma, bile, and urine) was deproteinized by adding 250 µL of methanol and 1 mL ethyl acetate and centrifuging at 10,000 rpm for 5 min. An 1.2-mL aliquot of the supernatant was evaporated under a gentle stream of nitrogen gas, and the residue was reconstituted in a 50-µL aliquot of the mobile phase (water:acetonitrile:0.1 M phosphoric acid = 61:31:8 v/v/v, pH 3.5). A 30-µL aliquot of the reconstituted solution was injected into the HPLC system, which consisted of a Hitachi L-7110 pump (Hitachi, Japan), a Shimadzu RF 535 fluorescence detector (Shimadzu, Japan; excitation 470 nm, emission 565 nm), a Hitachi D-7500 integrator and a C 18 column (Shisheido, CAPCELL PAK, 4.6 × 250 mm, 5 µm). The flow rate of the mobile phase was set at 1 mL/min. The eluent resulted in sharp, well-resolved peaks corresponding to doxorubicin (internal standard, 6.8 min), daunorubicinol (11.7 min), and daunorubicin (14.4 min). The calibration curves for daunorubicin were linear over the concentration range of 0.05-25.0 µg/mL for plasma, bile, and urine samples, and the interand intra-day coefficients of variation for daunorubicin were below 14.5%. The calibration curve for daunorubicinol was linear over the concentration range of 0.05-2.50 µg/mL for plasma, and the inter-and intra-day coefficients of variation of daunorubicinol were below 10.0%.
Data analysis for the in vitro uptake into isolated hepatocytes and cLPM vesicles
To estimate the relevant uptake kinetic parameters for both isolated hepatocyte and cLPM vesicle systems, the initial uptake rate-concentration data from each experimental system were fitted to a modified Michaelis-Menten equation (Eq. 1), using WinNonlin (ver. 5.1., Pharsight, Mountain View, CA):
where V o is the initial uptake rate of daunorubicin, S is the initial concentration of daunorubicin in the medium, and K d is a passive diffusion constant. V max and K m represent the maximum uptake rate and medium concentration at half of the maximal uptake rate, respectively. The intrinsic clearance for the uptake (CL int ) was obtained from V max /K m .
Pharmacokinetic analysis
The area under the plasma concentration-time curve from time zero to 3 h (AUC 0-3h ) was calculated using a trapezoidal rule and the area from the last datum point to time infinity was estimated by dividing the last measured plasma concentration by the terminal phase rate constant. Standard methods (26) were used to calculate the systemic clearance (CL) and apparent volume of distribution at a steady state (V d ) using noncompartmental analysis (WinNonlin, ver. 5.1.; Pharsight, Mountain View, CA). The apparent urinary (CL urine ) and biliary (CL bile ) clearances were calculated by dividing the total amount of daunorubicin excreted during the first 3 h into the urine (Ae u,0-3h ) and bile (Ae b,0-3h ) by the AUC for 3 h (AUC 0-3h ), respectively.
Statistical analysis
All data are expressed as the mean±standard deviation (S.D.). A p value of less than 0.01 was considered statistically significant using the nonparametric Mann-Whitney test between the two means for the unpaired data.
RESULTS
Pharmacokinetics of daunorubicin in CCl 4 -EHI
The plasma concentration-time profiles of daunorubicin following intravenous administration of the drug as daunorubicin hydrochloride at a dose of 11.3 mg/mL/kg and relevant pharmacokinetic parameters for control and CCl 4 -EHI rats are shown in Figure 1 and Table 1 . The plasma concentration of daunorubicin was generally higher in CCl 4 -EHI rats compared to control rats ( Figure 1A) . As a result, the AUC of daunorubicin was increased by 1.64 times (p<0.01) compared to the control value, and consequently, the systemic clearance (CL) of the drug was decreased by 34% in CCl 4 -EHI rats. No significant change was observed in the apparent volume of distribution at a steady state (V d ).
In CCl 4 -EHI rats, no significant changes were observed in the urinary recovery of the drug during the first 3 h ( Figure 1C and Ae u,0-3h in Table  1 ), whereas the biliary recovery of the drug during the first 3 h was increased by 1.2 times (p<0.01, Figure 1D and Ae b,0-3h in Table 1 ). The plasma profile of daunorubicinol, the major metabolite of daunorubicin, was generally lower in CCl 4 -EHI rats compared to control rats ( Figure  1B) , and the AUC m,0-3h of daunorucinol was decreased by 34% compared to control rats (p<0.01, Table 1 ). As the consequence of these changes, the apparent urinary (CL urine ) and biliary (CL bile ) clearance of the drug remained unchanged (Table 1) .
In vitro transport of daunorubicin
For high concentrations of the drug, CCl 4 -EHI decreased the initial uptake rate of daunorubicin into hepatocytes (Figure 2A) . The negative slope of the Eadie-Hofstee plot (Figure 2A, inset) suggests the involvement of a carrier-mediated transport mechanism in the sinusoidal uptake of the drug in control and CCl 4 -EHI rats. A nonlinear regression assuming a carrier-mediated process and passive diffusion in the uptake of the drug (Eq. 1) demonstrated a significant decrease in V max (p<0.01), but not in K m ( Table 2 ), suggesting that the amount of relevant transporters for sinusoidal uptake was decreased without influencing their affinity for daunorubicin in rats with CCl 4 -EHI. As a result, a slight decrease (20%, p<0.01) in the intrinsic clearance (CL int ) for sinusoidal uptake was observed for rats with CCl 4 -EHI ( Table 2 ). The passive diffusion clearance of the drug across the sinusoidal membrane (K d ) also decreased slightly with CCl 4 -EHI (Table 2) .
Contrary to the decrease in sinusoidal uptake, CCl 4 -EHI increased the uptake of daunorubicin into cLPM vesicles for all concentrations examined ( Figure 2B ). The EadieHofstee transformation indicated that carriermediated transport was involved in the canalicular excretion of daunorubicin ( Figure 2B, inset) , which is consistent with previous reports (27) . A nonlinear regression using Eq. 1 revealed profound (p<0.01, each) increases in the values of V max (2 times), CL int (1.7 times), and K d (1.7 times), with no change in K m ( Table 2 ), suggesting that the canalicular excretion of daunorubicin, contrary to sinusoidal uptake, is significantly increased in rats with CCl 4 -EHI.
Liver microsomal degradation of daunorubicin
To examine the metabolism of daunorubicin, we prepared liver microsomes from control and CCl 4 -EHI rats. The protein yield (23.4±0.79 mg/g liver for control, 21.1±1.2 mg/g liver for CCl 4 -EHI) was not changed, whereas the total CYP content (0.51±0.08 nmole/mg protein for control, 0.35±0.09 nmole/mg protein for CCl 4 -EHI) was decreased in rats with CCl 4 -EHI (p<0.01). Daunorubicin was fairly stable in the absence of an NADPH-regenerating system after incubation at 37 o C for 15 min ( Figure 3A) . On adding an NADPH-regenerating system, a significant amount of daunorubicin disappeared (60% disappearance in 15 min) for control, whereas this was significantly retarded (i.e., changed to a 30% disappearance in 15 min) in the CCl 4 -EHI rats ( Figure 3A) , suggesting that the metabolism of daunorubicin is decreased in rats with CCl 4 -EHI. The metabolic activity calculated from the slope of the concentration decline curve ( Figure 3A ) was 3.66±0.8 and 1.60±0.4 nmole/h (p<0.01) for control and CCl 4 -EHI microsomes, respectively, amounting to a 56% decrease with CCl 4 -EHI ( Figure 3B ). 
DISCUSSION
When hepatic injury is induced, changes in the elimination of xenobiotics are expected because the liver plays an important role in the metabolism and excretion of xenobiotics. The results presented in this study indicated that CCl 4 -EHI affects the pharmacokinetics of daunorubicin. That is, after the intravenous administration of daunorubicin, the AUC was increased by 1.6 times, whereas CL was reduced by 34% compared to the controls. The apparent urinary clearance (CL urine ) was not changed in CCl 4 -EHI rats, indicating that the change in the pharmacokinetics of daunorubicin caused by CCl 4 -EHI is unlikely to be associated with renal excretion. This suggests that a change in the hepatic disposition is responsible for the change in the pharmacokinetics of daunorubicin.
It has been reported that active transport processes are involved in the hepatobiliary elimination of daunorubicin, and CCl 4 -EHI affects the processes (15, 27) . However, the relevant mechanisms have not been elucidated systemically. The total in vitro sinusoidal uptake clearance (i.e., CL int + K d ) was decreased by 17% in CCl 4 -EHI (Table 2 ). In the sinusoidal uptake of daunorubicin into hepatocytes, passive diffusion appears to play a greater role than active transport because the K d is approximately 2 times greater than that of CL int for both control and CCl 4 -EHI rats. This may be associated with the high lipophilicity of the drug. The active sinusoidal uptake might be mediated by sinusoidal organic cation transporters (e.g., OCT1) considering that daunorubicin is cationic at physiological pH. In the cLPM vesicles, the CL int was 3.7 times greater than the K d for both control and CCl 4 -EHI rats 
-EHI rats (•). (B)
Concentration dependency for the initial uptake rate of daunorubicin (5-500 μM) into cLPM vesicles from control (○) and CCl 4 -EHI rats (•) in the presence of ATP. The curves were generated from the estimated kinetic parameters in Table 2 . Each point represents the mean ± standard deviation of triplicate measurements from three different batches of hepatocytes and cLPM vesicle preparations. The Eadie-Hofstee transformation of the initial uptake rate is shown in the inset. * : Significantly different from control rats (p<0.01).
( (30,31). Therefore, the increased expression of Pgp on canalicular membranes in CCl 4 -EHI rats (15) (15) . The decrease appears to be associated with the increase in the canalicular excretion under the decreased hepatic uptake ( Table 2 ). The sinusoidal K d was decreased, whereas the canalicular K d was increased by CCl 4 -EHI (Table 2) , although the underlying mechanism for this discrepancy is currently unknown. Similar results have been reported previously; the pretreatment of CCl 4 increased the membrane fluidity of the mitochondrial outer membrane, but decreased that of the mitochondrial inner membrane (32) . Further investigation is necessary to explain this discrepancy.
Although the in vitro intrinsic canalicular excretion clearance (CL int ) of daunorubicin was increased by 1.7 times, it had a negligible effect on the biliary excretion of daunorubicin in CCl 4 -EHI, possibly because of the decrease in the in vitro intrinsic sinusoidal uptake clearance (CL int ). As a result, sinusoidal uptake, rather than canalicular excretion, appears to govern the overall hepatobiliary excretion and pharmacokinetics of daunorubicin. In addition to the sinusoidal uptake into hepatocytes, hepatic metabolism appears to be most affected by the CCl 4 -EHI. The significant decrease in the systemic clearance in the absence of decreases in the apparent urinary (CL urine ) and biliary (CL bile ) clearances (Table 1) implies that CCl 4 -EHI reduces the metabolism or degradation of daunorubicin in the liver. This hypothesis is supported by the fact that CCl 4 -EHI significantly retarded the in vitro degradation of the drug in the liver microsomes (Figure 3) , and decreased the CYP content in the microsomes from 0.51 to 0.35 nmole/mg protein. Moreover, CCl 4 treatment was reported to cause a marked reduction in the expression of CYP 2B1 (18) , which is responsible for the biotransformation of daunorubicin (4) . Therefore, the reduced expression of the relevant metabolizing enzyme in the liver and subsequently reduced metabolism of the drug in the liver ( Figure 1B and Figure 3 ), appear to be responsible for the decreased systemic clearance and increased AUC of daunorubicin in rats with CCl 4 -EHI.
CCl 4 -induced hepatic injury is known to accompany hyperbilirubinemia, steatosis, liver cirrhosis, and necrosis (11, 33, 34) . Moreover, CCl 4 , along with acetaminophen and alcohol, has been classically used in rodent models to investigate mechanisms of hepatotoxicity relevant to human exposure (35) . Drug or chemicalinduced liver injury accounted for more than 50% of all cases of acute liver failure in the United States from 1997 to 2002 (36) . Toxicity resulting from these chemicals induced oxidative stress and altered cellular redox status. The dysregulated redox status, in turn, activated adaptive mechanism to change the expression of hepatic transporters and metabolizing enzymes as well as detoxication genes. This coordinated regulation altered the expression to limit the accumulation of chemicals within the hepatocyte (i.e., in general, decreased hepatic uptake and increased canalicular efflux) (33, 35) , which is consistent with our results and implicates altered hepatic function and pharmacokinetics of drugs.
Therefore, in patients with chemical or drug induced hepatotoxicity, adjustment of dosage regimens for drugs that are substrates of these transporters or metabolizing enzymes would be needed (35, 37) , with particular care on that functional changes of transporters are multidirectional as a function of time after the hepatotoxicity induction (15) .
ABBREVIATIONS
Ae b,0-3h , cumulative amount excreted into bile during the first 3 h; Ae u,0-3h , cumulative amount excreted into urine during the first 3 h; AUC, area under the plasma concentration-time curve; AUC m,0-3h , area under the plasma concentrationtime curve for metabolite from time zero to 3 h; Bsep, bile salt export pump; CCl 4 , carbon tetrachloride; CCl 4 -EHI, CCl 4 -induced experimental hepatic injury; CL, systemic clearance; CL bile , apparent biliary clearance; CL urine , apparent urinary clearance; CL int , intrinsic clearance; cLPM, canalicular liver plasma membrane; CYP, cytochrome P-450; Mrp, multidrug-resistance related protein; ntcp, Na + /taurocholate cotransporting polypeptide; Oatp, organic anion transporting polypeptide; OCT, organic cation transporter; P-gp, Pglycoprotein; V d , apparent volume of distribution at a steady state
